Relationship between the expressions of CLIC4 and SNHG3 and the prognosis of patients with Stage Ⅰ-Ⅱ ovarian cancer

doi:10.3969/j.issn.1673-8640.2021.010.008

Abstract

Abstract:

Objective To investigate the relationship between the expressions of chloride intracellular channel protein 4（CLIC4）and small nucleolar RNA host gene 3（SNHG3）and the prognosis of patients with Stage Ⅰ-Ⅱ ovarian cancer. Methods A total of 113 patients with Stage Ⅰ-Ⅱ ovarian cancer（ovarian cancer group） and 76 patients with benign ovarian tumors（control group） were enrolled. The expression of CLIC4 was determined by immuno-histochemistry. The relative expression of SNHG3 was determined by real-time fluorescence quantitative polymerase chain reaction（PCR）. The general clinical data were collected. The relationship between the expressions of CLIC4 and SNHG3 and the prognosis of ovarian cancer（survival） was evaluated by Kaplan-Meier survival curve analysis. The influence factors for the prognosis of Stage Ⅰ-Ⅱ ovarian cancer were analyzed by Cox ratio regression analysis. Results The high and positive expression rate of CLIC4,the percentage of CLIC4 by immunohistochemistry and the relative expression of SNHG3 in ovarian cancer group were higher than those in control group （P<0.001）. The high expression of CLIC4 was related to the pathological type （serous carcinoma）,histological grade （G2 or G） and clinical stage （Stage Ⅱ） of patients with Stage Ⅰ-Ⅱ ovarian cancer （P<0.05）. There was statistical significance in the expression of CLIC4 in patients with serous cancer,mucinous cancer and endometrioid cancer （P=0.000）,and there was no statistical significance between the other pathological types （P>0.05）. The high expression of SNHG3 was related to the histological grade and clinical stage of ovarian cancer （P<0.05）. The overall survival rate （OS） and disease progression-free survival rate （PFS） of CLIC4 high expression group were lower than those of CLIC4 low expression group （P<0.05）. The OS and PFS of SNHG3 high expression group were lower than those of SNHG3 low expression group （P<0.05）. Carbohydrate antigen 125 （CA125）,human epididymis protein 4 （HE4）,CLIC4,SNHG3,histological grade and clinical stage were influencing factors for the prognosis （survival） of patients with Stage Ⅰ-Ⅱ ovarian cancer. Conclusions The high expressions of CLIC4 and SNHG3 are correlated with the clinical characteristics and prognosis of Stage Ⅰ-Ⅱ ovarian cancer. CLIC4 and SNHG3 are influence factors for the prognosis and survival of Stage Ⅰ-Ⅱ ovarian cancer patients.

Key words: Chloride intracellular channel protein 4, Small nucleolar RNA host gene 3, Long non-coding RNA, Ovarian cancer

CLC Number:

R446.1

XUE Yan, WANG Jiajia, WANG Fuxiang, REN Qiuwei. Relationship between the expressions of CLIC4 and SNHG3 and the prognosis of patients with Stage Ⅰ-Ⅱ ovarian cancer[J]. Laboratory Medicine, 2021, 36(10): 1026-1032.

Figures/Tables 7

References 18

[1]	王莉, 江春, 陈春英. 可溶性B7-H4在早期卵巢癌诊断中的价值[J]. 中国现代医学杂志, 2014, 24(23):107-109.
[2]	OKUDELA K, KATAYAMA A, WOO T, et al. Proteome analysis for downstream targets of oncogenic KRAS-the potential participation of CLIC4 in carcinogenesis in the lung[J]. PLoS One, 2014, 9(2):e87193.
[3]	YAO Q, QU X, YANG Q, et al. CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer[J]. Oncol Rep, 2009, 22(3):541-548.
[4]	TAHERIAN-ESFAHANI Z, TAHERI M, DASHTI S, et al. Assessment of the expression pattern of mTOR-associated lncRNAs and their genomic variants in the patients with breast cancer[J]. J Cell Physiol, 2019, 234(12):22044-22056. DOI URL
[5]	ZHANG T, CAO C, WU D, et al. SNHG3 correlates with malignant status and poor prognosis in hepatocellular carcinoma[J]. Tumour Biol, 2016, 37(2):2379-2385. DOI URL
[6]	PRAT J. Ovarian,fallopian tube and peritoneal cancer staging:rationale and explanation of new FIGO staging 2013[J]. Best Pract Res Clin Obstet Gynaecol, 2015, 29(6):858-869. DOI URL
[7]	NASIOUDIS D, WILSON E, MASTROYANNIS S A, et al. Prognostic significance of elevated pre-treatment serum CA-125 levels in patients with stage Ⅰ ovarian sex cord-stromal tumors[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 238:86-89. DOI URL
[8]	邓森灵, 兰代群, 曹雅文, 等. 血清miR-222、HE4及CA125水平联合ROMA 指数对上皮性卵巢癌的诊断价值[J]. 现代妇产进展, 2021, 30(3):189-192.
[9]	GUO J, YANG W L, PAK D, et al. Osteopontin,macrophage migration inhibitory factor and anti-interleukin-8 autoantibodies complement CA125 for detection of early stage ovarian cancer[J]. Cancers(Basel), 2019, 11(5):596.
[10]	和晓利, 张菊新, 靖爽, 等. 血清人附睾蛋白4和糖链抗原125诊断卵巢癌的价值[J]. 中华实用诊断与治疗杂志, 2017, 31(3):245-247.
[11]	黄斌. HE4联合CA125对早期卵巢癌的诊断价值研究[J]. 实用癌症杂志, 2016, 31(5):720-722.
[12]	王秋兰, 薛永杰, 韩涛. 人胃癌组织中CLIC4基因表达与微卫星不稳定性的关系[J]. 肿瘤防治研究, 2016, 43(7):572-576.
[13]	SINGHA B, HARPER S L, GOLDMAN A R, et al. CLIC1 and CLIC4 complement CA125 as a diagnostic biomarker panel for all subtypes of epithelial ovarian cancer[J]. Sci Rep, 2018, 8(1):14725. DOI URL
[14]	YAO Q, QU X, YANG Q, et al. CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer[J]. Oncol Rep, 2009, 22(3):541-548.
[15]	SONG Y, PAN Y, LIU J. Functional analysis of lncRNAs based on competitive endogenous RNA in tongue squamous cell carcinoma[J]. Peer J, 2019, 7:e6991. DOI URL
[16]	ZHANG P F, WANG F, WU J, et al. LncRNA SNHG3 induces EMT and sorafenib resistance by modulating the miR-128/CD151 pathway in hepatocellular carcinoma[J]. J Cell Physiol, 2019, 234(3):2788-2794. DOI URL
[17]	罗涛, 彭细娟, 杨彦龙. 长链非编码RNA SNHG3在神经胶质瘤中的表达及临床意义[J]. 解放军医学院学报, 2018, 39(12):1093-1096.
[18]	HONG L, CHEN W, WU D, et al. Upregulation of SNHG3 expression associated with poor prognosis and enhances malignant progression of ovarian cancer[J]. Cancer Biomark, 2018, 22(3):367-374. DOI URL

组别	例数	年龄/岁	BMI/（kg/m²）	经产次数/次	CA125/（U/mL）	HE4/（pmol/L）	ROMA指数
对照组	76	48.79±9.06	23.85±2.04	2（0~4）	51.29±20.36	49.33±21.56	6.58±3.19
卵巢癌组	113	49.83±9.94	24.06±2.77	2（0~5）	207.23±139.85	241.02±144.88	57.52±21.63
统计值		1.024	1.598	0.654	24.653	25.242	30.263
P值		0.274	0.232	0.428	0.000	0.000	0.000

组别	例数	年龄/岁	BMI/（kg/m²）	经产次数/次	CA125/（U/mL）	HE4/（pmol/L）	ROMA指数
对照组	76	48.79±9.06	23.85±2.04	2（0~4）	51.29±20.36	49.33±21.56	6.58±3.19
卵巢癌组	113	49.83±9.94	24.06±2.77	2（0~5）	207.23±139.85	241.02±144.88	57.52±21.63
统计值		1.024	1.598	0.654	24.653	25.242	30.263
P值		0.274	0.232	0.428	0.000	0.000	0.000

组别	免疫组化积分/%	CLIC4表达				高表达率/%
组别	免疫组化积分/%	阴性	弱阳性	阳性	强阳性	高表达率/%
对照组	19.85±3.71	53（69.74）	16（21.05）	7（9.21）	0（0）	7（9.21）
卵巢癌组	48.52±8.06	19（16.82）	22（19.46）	53（46.90）	19（16.82）	72（63.72）
统计值	15.302					55.492
P值	0.000					0.000

组别	免疫组化积分/%	CLIC4表达				高表达率/%
组别	免疫组化积分/%	阴性	弱阳性	阳性	强阳性	高表达率/%
对照组	19.85±3.71	53（69.74）	16（21.05）	7（9.21）	0（0）	7（9.21）
卵巢癌组	48.52±8.06	19（16.82）	22（19.46）	53（46.90）	19（16.82）	72（63.72）
统计值	15.302					55.492
P值	0.000					0.000

临床病理特征	CLIC4				SNHG3
临床病理特征	低表达	高表达	χ²值	P值	低表达	高表达	χ²值	P值
年龄			1.031	0.310			2.180	0.140
<50岁	17（31.48）	37（68.52）			20（37.04）	34（62.96）
≥50岁	24（40.68）	35（59.32）			30（50.85）	29（49.15）
病理类型			20.878	0.000			5.806	0.121
浆液性癌	7（21.88）	25（78.12）			13（40.63）	19（59.37）
黏液性癌	16（28.57）	40（71.43）			21（37.50）	35（62.50）
子宫内膜样癌	16（80.00）	4（20.00）			12（60.00）	8（40.00）
透明细胞癌	2（40.00）	3（60.00）			4（80.00）	1（20.00）
组织学分级			7.456	0.006			9.397	0.002
G1级	38（42.70）	51（57.30）			46（51.69）	43（48.31）
G2~G3级	3（12.50）	21（87.50）			4（16.67）	20（83.33）
临床分期			7.506	0.006			10.731	0.001
Ⅰ期	36（43.90）	46（56.10）			44（53.66）	38（46.34）
Ⅱ期	5（16.13）	26（83.87）			6（19.35）	25（80.65）
肿瘤直径/cm			1.304	0.253			2.040	0.153
>10	31（39.74）	47（60.26）			38（48.72）	40（51.28）
≤10	10（28.57）	25（71.43）			12（34.29）	23（65.71）